Cargando…

A hybrid multiscale model for investigating tumor angiogenesis and its response to cell-based therapy

Angiogenesis, a formation of blood vessels from an existing vasculature, plays a key role in tumor growth and its progression into cancer. The lining of blood vessels consists of endothelial cells (ECs) which proliferate and migrate, allowing the capillaries to sprout towards the tumor to deliver th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hendrata, Melisa, Sudiono, Janti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597970/
https://www.ncbi.nlm.nih.gov/pubmed/29226860
http://dx.doi.org/10.3233/ISB-170469
_version_ 1783430675561447424
author Hendrata, Melisa
Sudiono, Janti
author_facet Hendrata, Melisa
Sudiono, Janti
author_sort Hendrata, Melisa
collection PubMed
description Angiogenesis, a formation of blood vessels from an existing vasculature, plays a key role in tumor growth and its progression into cancer. The lining of blood vessels consists of endothelial cells (ECs) which proliferate and migrate, allowing the capillaries to sprout towards the tumor to deliver the needed oxygen. Various treatments aiming to suppress or even inhibit angiogenesis have been explored. Mesenchymal stem cells (MSCs) have recently been undergoing development in cell-based therapy for cancer due to their ability to migrate towards the capillaries and induce the apoptosis of the ECs, causing capillary degeneration. However, further investigations in this direction are needed as it is usually difficult to preclinically assess the efficacy of such therapy. We develop a hybrid multiscale model that integrates molecular, cellular, tissue and extracellular components of tumor system to investigate angiogenesis and tumor growth under MSC-mediated therapy. Our simulations produce angiogenesis and vascular tumor growth profiles as observed in the experiments. Furthermore, the simulations show that the effectiveness of MSCs in inducing EC apoptosis is density dependent and its full effect is reached within several days after MSCs application. Quantitative agreements with experimental data indicate the predictive potential of our model for evaluating the efficacy of cell-based therapies targeting angiogenesis.
format Online
Article
Text
id pubmed-6597970
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-65979702019-07-01 A hybrid multiscale model for investigating tumor angiogenesis and its response to cell-based therapy Hendrata, Melisa Sudiono, Janti In Silico Biol Research Article Angiogenesis, a formation of blood vessels from an existing vasculature, plays a key role in tumor growth and its progression into cancer. The lining of blood vessels consists of endothelial cells (ECs) which proliferate and migrate, allowing the capillaries to sprout towards the tumor to deliver the needed oxygen. Various treatments aiming to suppress or even inhibit angiogenesis have been explored. Mesenchymal stem cells (MSCs) have recently been undergoing development in cell-based therapy for cancer due to their ability to migrate towards the capillaries and induce the apoptosis of the ECs, causing capillary degeneration. However, further investigations in this direction are needed as it is usually difficult to preclinically assess the efficacy of such therapy. We develop a hybrid multiscale model that integrates molecular, cellular, tissue and extracellular components of tumor system to investigate angiogenesis and tumor growth under MSC-mediated therapy. Our simulations produce angiogenesis and vascular tumor growth profiles as observed in the experiments. Furthermore, the simulations show that the effectiveness of MSCs in inducing EC apoptosis is density dependent and its full effect is reached within several days after MSCs application. Quantitative agreements with experimental data indicate the predictive potential of our model for evaluating the efficacy of cell-based therapies targeting angiogenesis. IOS Press 2019-05-30 /pmc/articles/PMC6597970/ /pubmed/29226860 http://dx.doi.org/10.3233/ISB-170469 Text en © 2019 – IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Hendrata, Melisa
Sudiono, Janti
A hybrid multiscale model for investigating tumor angiogenesis and its response to cell-based therapy
title A hybrid multiscale model for investigating tumor angiogenesis and its response to cell-based therapy
title_full A hybrid multiscale model for investigating tumor angiogenesis and its response to cell-based therapy
title_fullStr A hybrid multiscale model for investigating tumor angiogenesis and its response to cell-based therapy
title_full_unstemmed A hybrid multiscale model for investigating tumor angiogenesis and its response to cell-based therapy
title_short A hybrid multiscale model for investigating tumor angiogenesis and its response to cell-based therapy
title_sort hybrid multiscale model for investigating tumor angiogenesis and its response to cell-based therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597970/
https://www.ncbi.nlm.nih.gov/pubmed/29226860
http://dx.doi.org/10.3233/ISB-170469
work_keys_str_mv AT hendratamelisa ahybridmultiscalemodelforinvestigatingtumorangiogenesisanditsresponsetocellbasedtherapy
AT sudionojanti ahybridmultiscalemodelforinvestigatingtumorangiogenesisanditsresponsetocellbasedtherapy
AT hendratamelisa hybridmultiscalemodelforinvestigatingtumorangiogenesisanditsresponsetocellbasedtherapy
AT sudionojanti hybridmultiscalemodelforinvestigatingtumorangiogenesisanditsresponsetocellbasedtherapy